BioSpace News Archive

Fact.MR: The optometry equipment market revenue surpassed US$3.8 Bn for 2018, according to Fact.MR. The optometry equipment overall market is expected to gain US$ 2 Billion worth incremental opportunity by 2029.

The global bioprocessing analytics equipment market is expected to rise at a large scale due to growing need for biotherapeutics from biopharmaceutical industry that is met by performing process optimization.

Nicox SA, an international ophthalmology company, announced that its exclusive global licensee Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., has received approval for VYZULTA®, 0.024% in the United Arab Emirates.

The European Commission has approved Sanofi and Regeneron’s PD-1 inhibitor Libtayo® to treat adults with locally advanced or metastatic basal cell carcinoma who have progressed on or are intolerant to a hedgehog pathway inhibitor.

Aurinia Pharmaceuticals Inc. announced that the Company’s licensing partner, Otsuka Pharmaceutical Europe Ltd., filed an initial Marketing Authorization Application for voclosporin for the treatment of lupus nephritis to the European Medicines Agency. LN is a complication of the autoimmune disease systemic lupus erythematosus that seriously impacts the kidneys.

Centogene N.V., a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced the voting results of the Company’s Annual General Meeting.

Cybin Inc., a biotechnology company focused on progressing psychedelic therapeutics, announced that Doug Drysdale, Chief Executive Officer, will participate in a virtual fireside chat at Grizzle Psychedelics Con on June 28, 2021.

Regulus Therapeutics Inc., a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, announced the presentation of additional data from the first cohort of patients in the Company’s Phase 1b clinical trial of RGLS4326 for the treatment of autosomal dominant polycystic kidney disease, as well as new preclinical data from relevant animal models of the disease.

Evaxion Biotech A/S, a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced the acceptance of a new scientific paper by the International Conference on Machine Learning.

Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma